# Modulation of Gut Microbiota by Rifaximin in PD Patients

> **NCT03958708** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Taipei Medical University Shuang Ho Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Parkinson Disease
- Inflammation

## Interventions

- **DRUG:** Rifaximin 550 MG

## Key facts

- **NCT ID:** NCT03958708
- **Lead sponsor:** Taipei Medical University Shuang Ho Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-13
- **Primary completion:** 2020-05-12
- **Final completion:** 2020-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03958708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03958708, "Modulation of Gut Microbiota by Rifaximin in PD Patients". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03958708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*